Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FLT3 exon 14 ins |
Therapy | Decitabine + Sorafenib |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Decitabine + Sorafenib | Case Reports/Case Series | Actionable | In a clinical study, treatment with Nexavar (sorafenib) in combination with Dacogen (decitabine) was well tolerated and resulted in an overall response rate of 83% (5/6, 1 complete remission (CR) and 4 CR with incomplete count recovery) with a median overall survival of 155 days in patients with acute myeloid leukemia (AML) harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation, and the combination synergistically inhibited growth of a FLT3-ITD positive AML cell line in culture (PMID: 26297284). | 26297284 |
FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Decitabine + Sorafenib | Guideline | Actionable | Nexavar (sorafenib) in combination with Dacogen (decitabine) is included in guidelines for patients with relapsed or refractory acute myeloid leukemia harboring a FLT3 internal tandem duplication (FLT3-ITD) mutation (NCCN.org). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... | |
(26297284) | Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia. | Full reference... |